Oxygen Therapy Device Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, medical device industry reports, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH), European Medicines Agency (EMA), European Commission Medical Device Coordination Group (MDCG), International Organization for Standardization (ISO 13485/ISO 18562), World Health Organization (WHO) Global Health Observatory, US Centers for Disease Control and Prevention (CDC) National Center for Health Statistics, National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI), National Center for Biotechnology Information (NCBI/PubMed), Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society (ATS), European Respiratory Society (ERS), American Lung Association, British Thoracic Society, Japan Society for Respiratory Care, Australian Institute of Health and Welfare (AIHW), EU Eurostat Health Database, Centers for Medicare & Medicaid Services (CMS), US Department of Health and Human Services (HHS), Health Canada, Therapeutic Goods Administration (TGA) Australia, Pharmaceuticals and Medical Devices Agency (PMDA) Japan, China National Medical Products Administration (NMPA), and national health ministry reports from key markets. These sources were used to collect respiratory disease prevalence statistics, regulatory approval data, clinical safety and efficacy studies, reimbursement policies, demographic trends, hospital admission data, and market landscape analysis for oxygen concentrators, liquid oxygen systems, oxygen cylinders, portable oxygen devices, and oxygen accessories.

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. Sources from the supply side included CEOs, VPs of Product Development, regulatory affairs heads, R&D directors, and commercial directors from oxygen therapy device manufacturers, medical gas suppliers, and OEMs. Pulmonologists, respiratory therapists, critical care physicians, hospital procurement leads, home healthcare service providers, medical device distributors, and reimbursement specialists from hospitals, home care settings, emergency medical services, and long-term care facilities comprised demand-side sources. Market segmentation was validated across device types and technologies, product pipeline timelines were confirmed, and insights regarding clinical adoption patterns, pricing strategies, reimbursement dynamics, and the transition to home-based oxygen therapy and portable concentrators were gathered through primary research.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Global market valuation was derived through revenue mapping, device unit shipment analysis, and procedure volume assessment. The methodology included:

Identification of 40+ key manufacturers across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Product mapping across oxygen concentrators (stationary and portable), liquid oxygen systems, oxygen cylinders, oxygen accessories (masks, cannulas, humidifiers), and hybrid oxygen delivery technologies

Analysis of reported and modeled annual revenues specific to oxygen therapy device portfolios

Coverage of manufacturers representing 70–75% of global market share in 2024

Extrapolation using bottom-up (device unit shipments × ASP by country/region, segmented by application and end-use setting) and top-down (manufacturer revenue validation across continuous flow, pulse dose, and hybrid technology platforms) approaches to derive segment-specific valuations for COPD, asthma, respiratory distress syndrome, sleep apnea, and cystic fibrosis applications